BIIB – biogen inc. (US:NASDAQ)
Stock Stats
News
12/22
11:50 am
biib
Low
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
12/22
11:20 am
biib
Low
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
12/19
09:18 am
biib
Medium
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
12/19
05:24 am
biib
Medium
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
12/12
12:01 pm
biib
Low
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.
10/31/2025
04:02 pm
BIIB
-1.8%
BEAT
10/30/2025
04:03 pm
BIIB
3.1%
BEAT
10/30/2025
06:17 am
BIIB
4.3%
BEAT
7/31/2025
04:01 pm
BIIB
3.1%
BEAT
12/12
12:05 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
0.3%
12/12
12:05 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
0.3%
12/10
03:01 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
0.4%
12/10
03:01 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
0.4%
12/10
07:01 am
Downgrades
Hold
Reduce
HSBC Holdings plc
Medium
3.8%
12/3
04:43 pm
biib
Low
Form 4 BIOGEN INC. For: Dec 01 Filed by: Viehbacher Christopher
11/13
08:28 pm
biib
Low
Form SCHEDULE 13G/A BIOGEN INC. Filed by: PRIMECAP MANAGEMENT CO/CA/
11/10
08:15 am
biib
Low
Form SCHEDULE 13G BIOGEN INC. Filed by: STATE STREET CORP
11/4
04:13 pm
biib
Low
Form 4 BIOGEN INC. For: Oct 31 Filed by: Grogan Jane
10/30
06:32 am
biib
Medium
Form 10-Q BIOGEN INC. For: Sep 30
Show more
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3